Concord Wealth Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Concord Wealth Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.65K	Hold	200	–	–	﹤0.01%	601
2026 Q2	$7.42K	Buy	+200	New	+$6.07K	﹤0.01%	609
2026 Q1	–	Sell	-200	Closed	-$5.44K	–	221
2025 Q4	$5.44K	Hold	200	–	–	﹤0.01%	612
2025 Q3	$8.03K	Hold	200	–	–	﹤0.01%	563
2025 Q2	$6.65K	Hold	200	–	–	﹤0.01%	599
2025 Q1	$5.86K	Hold	200	–	–	﹤0.01%	566
2024 Q4	$6.57K	Hold	200	–	–	﹤0.01%	571
2024 Q3	$8.89K	Hold	200	–	–	﹤0.01%	566
2024 Q2	$8.62K	Hold	200	–	–	﹤0.01%	522
2024 Q1	$5.85K	Hold	200	–	–	﹤0.01%	636
2023 Q4	$4.45K	Hold	200	–	–	﹤0.01%	648
2023 Q3	$4.95K	Hold	200	–	–	﹤0.01%	719
2023 Q2	$5.66K	Hold	200	–	–	﹤0.01%	684
2023 Q1	$4.59K	Hold	200	–	–	﹤0.01%	684
2022 Q4	$5.62K	Buy	+200	New	+$5.64K	﹤0.01%	735
2022 Q3	–	Sell	-200	Closed	-$4K	–	176
2022 Q2	$4K	Hold	200	–	–	﹤0.01%	844
2022 Q1	$6K	Hold	200	–	–	﹤0.01%	858
2021 Q4	$7K	Buy	+200	New	+$8.05K	﹤0.01%	854

Other funds holding AGIO

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Virginia Retirement Systems Richmond, Virginia $16.3B AUM 35.33% 1-Year Est. Return

Concord Wealth Partners's AGIO Position: Q3 2026 in Review

Concord Wealth Partners held its Agios Pharmaceuticals (AGIO) position steady in Q3 2026 at 200 shares worth $6.65K. The position accounts for ﹤0.01% of the portfolio, ranked #601.

Concord Wealth Partners first reported a position in AGIO in Q4 2021 and has held it in 18 quarters since. The position peaked at $8.89K in Q3 2024. 64 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

Concord Wealth Partners held 200 shares of Agios Pharmaceuticals worth $6.65K as of Q3 2026.
Concord Wealth Partners left its Agios Pharmaceuticals share count unchanged in Q3 2026.
Agios Pharmaceuticals made up ﹤0.01% of Concord Wealth Partners's portfolio in Q3 2026, its #601 holding.
Concord Wealth Partners first reported a position in Agios Pharmaceuticals in Q4 2021 and has held it in 18 quarters since.
Concord Wealth Partners's Agios Pharmaceuticals position peaked at $8.89K in Q3 2024.
64 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on Concord Wealth Partners's 13F filing for Q3 2026, filed 2 Nov 2026.